Slide 1: Q3'22 Financial Results Overview
Agilent Technologies Q3’22 Financial Results Overview
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q3'22
Agilent Results Q3’22 A leading lab partner with unsurpassed capabilities and scale Q3’22 Financial Metrics Q3’22 Highlights • Revenues: $1.72B, +8.4% reported, • Growth: broad strength across our end markets, with Pharma and C&E +13.2% y/y core(1)(2) (-4.8% FX). once again delivering outstanding re
Slide 4: Growth in a $65B+ Market – Q3'22 Core Growth Results by End Market
Growth in a $65B+ Market – Q3’22 Core Growth(2) Results by End Market Continued momentum in Pharma and C&E Pharma & Biotech: Up 16% on broad strength across pharma, including BioPharma and small molecule, and across the Americas, China, and Europe. Chemical & Energy: Up 22% driven by continued s
Slide 5: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation, Informatics, and • Q3 core revenue performance reflected broad strength across end Consumables markets, with Pharma, Chemical & Energy, Food, and Environmental for Analytical Laboratories & Forensics all registering double-digit growth. O
Slide 6: Agilent CrossLab Group (ACG)
Agilent CrossLab Group (ACG) Analytical Laboratory • Q3 brought another quarter of double-digit Services growth performance for CrossLab, with all end markets and regions delivering core growth versus last year. Robust instrument sales and a +1ppt year-over-year increase in service agreement connect
Slide 7: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q3 core revenue growth of 3% after growing 37% last Pathology, Genomics, and Nucleic Acid Manufacturing year. Growth was driven by clinical cancer testing and NGS, while our NASD facility had a planned shutdown impacting year-on-year growth. • Announced that pr
Slide 8: Q4'22 and FY22 Guidance and Forward-looking Considerations
Q4’22 and FY22 Guidance and Forward-looking Considerations Based on July 31, 2022 Exchange Rates Q4’22 Guidance (1) FY22 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,750 $1,775 Net Revenue ($M) $6,750 $6,775 Y/Y Core Revenue Growth (2) 10.3% 11.8% Y/Y Core Revenue Growth (2) 9.
Slide 9: Q3'22 Financial Results Overview
Q3'22 Financial Results Overview